OKRA.ai collaborates with AWS for Health initiative from Amazon Web Services

OKRA.ai collaborates with AWS for Health initiative from Amazon Web Services

OKRA.ai has announced a collaboration with the AWS for Health initiative from Amazon Web Services (AWS) to help upskill pharmaceutical companies that are looking to harness technology to engage with physicians and lower the costs of commercialising new treatments.

AWS for Health is a new initiative featuring services and solutions from AWS and AWS Partners, built specifically for healthcare, biopharma, and genomics. The initiative makes it easier for health customers to select the right tools and partners for their highest-priority workloads across the health communities. For customers looking to accelerate deployments with solution-specific support, AWS for Health also identifies dedicated AWS health industry specialists, AWS Professional Services teams, and leading AWS Partners in each solution area.

Pharmaceutical companies are determined to leverage data from the entire healthcare industry to drive personalised engagement and scientific partnerships with healthcare professionals. Engagement habits and preferences of healthcare providers (HCPs) have evolved rapidly over the past 18 months and as new science emerges, understanding how to drive timely, meaningful interactions with HCPs where patients will benefit most is critical. Historically, the process of delivering value to physicians and patients has been highly inefficient, based on rigid rules and limited data.

However, with the commercial brain built by OKRA.ai, life science companies have been able to connect vast amounts of data and make significant improvements in engaging and communicating with doctors, with agility and scale. The collaboration between OKRA.ai and AWS enables companies to roll out solutions quickly, internationally, and integrated within their existing infrastructure.

The adoption of AWS has enabled products to be set up in days rather than months, so that pharmaceutical companies can quickly reap the benefits even if existing datasets are complex and uncategorised.

OKRA.ai CEO Loubna Bouarfa said that they: “have built the most sophisticated AI brain for life sciences, with a range of AI applications that are empowering pharmaceutical staff to shorten the time to impact across critical parts of the value chain, including Value Access and Pricing, Medical Affairs and Commercial”.